TD Asset Management
SCPH

TD Asset Management’s scPharmaceuticals SCPH Stock Holding History

TD Asset Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-13,363
Closed -$166K – 1443
2018
Q1 		$166K Buy
13,363
+400
+3% +$5.38K ﹤0.01% 1323
2017
Q4 		$157K Buy
+12,963
New +$183K ﹤0.01% 1312

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TD Asset Management's SCPH Position: Q2 2018 in Review

TD Asset Management sold out of scPharmaceuticals (SCPH) in Q2 2018, closing a stake of 13,363 shares — an estimated $166K sold.

TD Asset Management first reported a position in SCPH in Q4 2017 and held it in 2 quarters. The position peaked at $166K in Q1 2018. 41 funds tracked by Wall St. Rank hold SCPH as of Q2 2018.

  • TD Asset Management reported no remaining scPharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • TD Asset Management sold 13,363 scPharmaceuticals shares in Q2 2018, an estimated $166K.
  • TD Asset Management first reported a position in scPharmaceuticals in Q4 2017 and held it in 2 quarters.
  • TD Asset Management's scPharmaceuticals position peaked at $166K in Q1 2018.
  • 41 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2018.

Based on TD Asset Management's 13F filing for Q2 2018, filed 31 Jul 2018.